Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 RSVPreF3 OA vaccine in adults 50–59 vs ≥60 years
jRCT2031220445Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, single-blind trial of GSK3003899A in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection (5 arms), sponsored by GSK. Primary endpoints: RSV-A neutralization antibody GMT ratio (healthy 50–59 vs ≥60), RSV-A neutralization antibody GMT ratio (increased-risk 50–59 vs ≥60) and 6 more. Started Nov 2022; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on jRCT2031220445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220445.